TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39702896
Drug: AS03-adjuvanted H7N9
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H7N9 vaccine
Study: 39703191
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) of the greater occipital nerves (GON) for 8-12 weeks, stimulating for 30 minutes twice daily
Study: 39703564
Drug: Tailored dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored dose-dense epirubicin/cyclophosphamide (EC) and docetaxel (D)
Study: 39705540
Drug: Voruciclib (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voruciclib (initially 100 mg daily continuously on a 28-day cycle, then changed to days 1-14 of a 28-day cycle); dose escalation stopped at 200 mg.
Study: 39705540
Drug: Voruciclib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voruciclib (200 mg on days 1-14 of a 28-day cycle);
Study: 39706212
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 2×10^6 allogeneic umbilical cord-derived mesenchymal stromal cells
Study: 39706209
Drug: Guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 200 mg given intravenously at weeks 0, 4, and 8 (induction)
Study: 39706209
Drug: Guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 200 mg given subcutaneously every 4 weeks (maintenance)
Study: 39706209
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg given subcutaneously every 8 weeks (maintenance)
Study: 39706632
Drug: NG101 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG101 (45 mg intrathecal injections, 6 doses every 5 days over 4 weeks)
Study: 39706761
Drug: Ledipasvir/Sofosbuvir (LDV/SOF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir (LDV/SOF) fixed dosing (45/200 mg)
Study: 39706803
Drug: Medication monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitoring (control group)
Study: 39707077
Drug: Risankizumab 1800
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab 1800 mg intravenous infusion once every 4 weeks for four doses
Study: 39707126
Drug: Pre-treatment contrast-enhanced
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment contrast-enhanced CT (CECT)
Study: 39707137
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT), administered once every other day for 30 min per session, totaling 14 sessions over 4 weeks
Study: 39707137
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (HCs), no SMT treatment
Study: 39707138
Drug: Juan Bi
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juan Bi Pill (JBP) combined with Methotrexate (MTX, 10 mg per week)
Study: 39707138
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with Methotrexate (MTX, 10 mg per week)
Study: 39707209
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen therapy (target SpO2 of ≥ 96%)
Study: 39707209
Drug: Conservative oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative oxygen therapy (target SpO2 of 88-92%)
Study: 39707239
Drug: Drug tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug tapering and treatment for underlying psychiatric disorders
Study: 39707287
Drug: Self-administered care
Normalized name: Lactomedi Self-care Trial Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered care recommendations (C-group)
Study: 39707407
Drug: Perioperative methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative methadone (0.10 mg/kg, administered intravenously at anesthesia induction)
Study: 39708086
Drug: 2G oral
Normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2G oral semaglutide (9 mg)
Study: 39708086
Drug: 2G oral
Normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2G oral semaglutide (4 mg)
Study: 39708086
Drug: 2G oral
Normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2G oral semaglutide (1.5 mg)
Study: 39708086
Drug: 2G oral
Normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2G oral semaglutide
Study: 39708224
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing from a Registered Dietitian (RDMI) during a 6-month intensive Food is Medicine (FIM) intervention
Study: 39708245
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (25-40 W applications, unlimited duration)
Study: 39708369
Drug: Topical ruxolitinib
Normalized name: ruxolitinib Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ruxolitinib 1.5% cream applied twice daily for 16 weeks
Study: 39708369
Drug: Topical ruxolitinib
Normalized name: ruxolitinib Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ruxolitinib treatment
Study: 39708537
Drug: Pressurized IntraThoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin (PITHAC) with doses of 7.5-12.5-35-70 mg/m2 heated at 39±1 °C
Study: 39708826
Drug: LVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVA therapy (2 g amoxicillin: 1 g twice a day)
Study: 39708826
Drug: HVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVA therapy (3 g amoxicillin: 1 g three times a day)
Study: 39708826
Drug: LVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVA therapy
Study: 39708826
Drug: HVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVA therapy
Study: 39709140
Drug: HEC88473 (30.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC88473 (30.6 mg)
Study: 39709140
Drug: HEC88473 (68.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC88473 (68.0 mg)
Study: 39709368
Drug: Multidisciplinary team
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidisciplinary team assessment and individualized treatment (MDT)
Study: 39709372
Drug: PULSAR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PULSAR with HyperArc© software, 11 Gray fraction of radiation every two weeks for a total of five fractions (total dose of 55 Gy)
Study: 39709402
Drug: L-PRF loaded
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF loaded with Metronidazole
Study: 39709493
Drug: Optimized restrictive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized restrictive fluid strategy (reducing fluid intake as much as possible in terms of maintenance fluids and fluids for drug dilution during the first 7 days)
Study: 39710508
Drug: Dostarlimab monotherapy
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab monotherapy (Arm A)
Study: 39710508
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of chemotherapy (Arm C)
Study: 39710693
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (20 mg/day on days 1-5, 10 mg/day on days 6-10)
Study: 39710693
Drug: Standard-dose dexamethasone
Normalized name: dexamethasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose dexamethasone (6 mg/day, days 1-10)
Study: 39710693
Drug: Standard-dose dexamethasone
Normalized name: dexamethasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose dexamethasone
Study: 39710697
Drug: Guideline-recommended ICG
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guideline-recommended ICG administration scheme
Study: 39711194
Drug: Propolis-based protocol
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis-based protocol for oral health in palliative care
Study: 39711425
Drug: Vancomycin administration
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin administration with negative pressure wound therapy (NPWT)
Study: 39711557
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for opioid use disorder (MOUD)
Study: 39711557
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to treatment initiation and retention
Study: 39711560
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention for acute myocardial infarction diagnosis and treatment
Study: 39711702
Drug: Citalopram with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram with prolonged grief disorder therapy (PGDT)
Study: 39711702
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo with PGDT
Study: 39711702
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo with clinical management
Study: 39711792
Drug: Intra-arterial cocktail
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial cocktail therapy with argatroban, dexamethasone, and edaravone administered for 30 minutes into the culprit artery after sufficient recanalization.
Study: 39712511
Drug: Dyadic Mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dyadic Mindfulness Self-Compassion intervention (six weekly sessions)
Study: 39713041
Drug: ANG1005 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANG1005 (600 mg/m2)
Study: 39713795
Drug: Pharmaceutical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical intervention to improve adherence to PPI; 122 out of 178 non-adherent patients received the intervention.
Study: 39713935
Drug: Domagrozumab (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab (an antibody-targeting myostatin)
Study: 39714546
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg capsules twice daily
Study: 39714936
Drug: Predictive low-glucose
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive low-glucose suspend insulin delivery
Study: 39714936
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump insulin delivery
Study: 39715568
Drug: Probiotic drink
Normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drink containing Bifidus ActiRegularis (5x10^8) strain, administered once a day for 15 consecutive days.
Study: 39715568
Drug: Non-pharmaceutical standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical standard care treatment (Control).
Study: 39715573
Drug: VDOT (Video
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDOT (Video Directly Observed Therapy)
Study: 39715573
Drug: UCDOT (Usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCDOT (Usual Care Directly Observed Therapy)
Study: 39715755
Drug: Toripalimab plus
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab plus chemotherapy
Study: 39716442
Drug: Acalabrutinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib treatment (n=23, NP group)
Study: 39716442
Drug: Acalabrutinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib treatment (n=18, PD group)
Study: 39716442
Drug: High surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High surface expression of CD49d and CD79b prior to acalabrutinib therapy
Study: 39716875
Drug: TAK-754 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAK-754 gene therapy
Study: 39717281
Drug: Derived DVT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derived DVT score with D-dimer cutoff of <0.5 µg/mL
Study: 39717517
Drug: Hydroxyurea therapy
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea therapy (daily administration, escalated to maximum tolerated dose over 36 months)
Study: 39717667
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa with chemotherapy (first-line treatment in cohorts A, B, C)
Study: 39717667
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa with chemotherapy (second-line treatment in cohort D)
Study: 39717777
Drug: SM17 (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM17 (2, 20, 70, 200, 400, 600, 1200 mg)
Study: 39717777
Drug: SM17 (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM17 (200, 400, 600 mg) every two weeks (Q2W) for a total of 3 doses
Study: 39717777
Drug: SM17 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM17 (up to 1200 mg)
Study: 39718172
Drug: Weekly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly dihydroartemisinin-piperaquine (approximately 2.5 mg per kg bodyweight dihydroartemisinin and 20 mg per kg bodyweight per day piperaquine)
Study: 39718172
Drug: Monthly sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine-pyrimethamine (approximately 25 mg per kg bodyweight sulfadoxine and 1.25 mg per kg bodyweight)
Study: 39718172
Drug: Weekly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly dihydroartemisinin-piperaquine
Study: 39718599
Drug: Egg-protein hydrolysate
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-protein hydrolysate (NWT-03) 5.7 g
Study: 39718747
Drug: belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: belantamab mafodotin (2.5 mg/kg on Day 1 of each 21-day cycle) plus bortezomib and dexamethasone (Arm A)
Study: 39718747
Drug: belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: belantamab mafodotin (2.5 mg/kg on Day 1 of the first 28-day cycle; 1.9 mg/kg on Day 1 of subsequent cycles) plus pomalidomide and dexamethasone (Arm B)
Study: 39718991
Drug: rVSV-ZEBOV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV-ZEBOV vaccine
Study: 39719248
Drug: Empowerment intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empowerment intervention (phone-based, 3 weekly sessions)
Study: 39719248
Drug: Education intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Education intervention (phone-based, 3 weekly sessions)
Study: 39719276
Drug: Questionnaire addressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questionnaire addressing general health, sleep quality, dietary habits, oral hygiene habits, and parafunctional habits
Study: 39719429
Drug: (R)-1,3-butanediol (BD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-1,3-butanediol (BD) 0.5 g/kg
Study: 39719488
Drug: Elinzanetant 120
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinzanetant 120 mg single dose
Study: 39719545
Drug: RENEW intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RENEW intervention using the digital gamification platform Kahoot! administered across eight weekly sessions
Study: 39719625
Drug: LHS intervention
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHS intervention during treatment phase
Study: 39721062
Drug: Glittre activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glittre activities of daily living (ADL) test
Study: 39721764
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenously administered at 1-hour preblock
Study: 39721764
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenously administered at the time of the block
Study: 39721764
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenously administered at 1 hour postblock
Study: 39721764
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenously administered at 2 hours postblock
Study: 39721764
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusions (placebo)
Study: 39721851
Drug: Ipatasertib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib (400 mg as a single agent, starting with a single dose for 7 days and continuous daily dosing for 21 days, followed by 7 days off schedule)
Study: 39721851
Drug: Ipatasertib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib (400 mg)
Study: 39722048
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection with electroporation
Study: 39722048
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection alone
Study: 39722048
Drug: Needle-free injection
Normalized name: Stratis Needle-Free Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free injection system (NFIS)
Study: 39722400
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg every 12 weeks
Study: 39722400
Drug: Placebo (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (switched to tildrakizumab 100 mg at W16)
Study: 39722558
Drug: TK-OS ML
Normalized name: TK-112690
DrugBank: TK-112690 (DB18822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TK-OS ML models
Study: 39722560
Drug: MenABCWY vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY vaccine (two doses six months apart)
Study: 39722560
Drug: MenACWY-CRM vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM vaccine (one dose)
Study: 39722695
Drug: High-dose testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose testosterone replacement therapy (TRT) with finasteride
Study: 39723536
Drug: Compound 21
Normalized name: COMPOUND 21
DrugBank: Buloxibutid (DB18038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 21 infusion
Study: 39723608
Drug: Self-administered intravaginal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2 g every other week for eight applications.
Study: 39723627
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (chemotherapy combination)
Study: 39724020
Drug: Active PBMT
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PBMT (LED therapy: DUO 240 [red at 660nm and near-infrared at 840nm] and BIOFLEX LDR-100 laser probe (660nm red light) and LD1-200 laser probe (825nm near-infrared light))
Study: 39724020
Drug: Placebo (non-effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (non-effective doses of LED array and laser therapy)
Study: 39725004
Drug: Post-treatment assessments
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment assessments
Study: 39725051
Drug: Placebo response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo response induced through saline injection plus verbal suggestion
Study: 39725450
Drug: Enhanced nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced nutrition package (iron and folic acid, monthly household supply of iodised salt, and micronutrient-fortified balanced energy protein supplement for undernourished women)
Study: 39725450
Drug: Enhanced infection
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced infection management package (genitourinary tract infection screening and treatment, and enhanced deworming)
Study: 39725795
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg daily
Study: 39725795
Drug: Bisoprolol 5-10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5-10 mg daily
Study: 39725982
Drug: SB-VF plus
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB-VF plus treatment as usual (TAU) (n = 41)
Study: 39725982
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n = 38)
Study: 39725982
Drug: SB-VF plus
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB-VF plus treatment as usual (TAU)
Study: 39727027
Drug: EC-IC bypass
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-IC bypass surgery with medical therapy